文献速递其他结缔组织病

系统性硬化症恶性肿瘤发病率:系统综述与荟萃分析

Incidence of malignancy in systemic sclerosis: A systematic review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2026-06-07

OBJECTIVE: SSc is associated with increased malignancy risk, a growing cause of mortality in SSc. However, standardised incidence ratios (SIR) vary widely across studies and different malignancy subtypes.…

要点

  • SSc患者总体恶性肿瘤风险显著升高,SIR为1.66(95%CI 1.32-2.08)。
  • 食管、肝脏、宫颈、肺及血液系统恶性肿瘤风险最高(SIR 3.35-13.95)。
  • SSc诊断与恶性肿瘤诊断之间平均间隔7.4年(95%CI 5.3-9.5)。

核心结论

  • SSc患者恶性肿瘤风险升高,尤其肺、血液系统和宫颈恶性肿瘤,SSc诊断至恶性肿瘤发生约间隔7年。

主要发现

  • 总体恶性肿瘤风险显著升高,SIR为1.66(95%CI 1.32-2.08)。
  • 食管、肝脏、宫颈、肺及血液系统恶性肿瘤风险最高,SIR范围为3.35-13.95。
  • 乳腺癌风险轻度升高(SIR 1.34,95%CI 1.00-1.80),但无统计学显著性。
  • 高质量研究证实上述关联,但食管恶性肿瘤除外;肝脏恶性肿瘤仅有一项高质量研究。
  • SSc诊断与恶性肿瘤诊断之间平均间隔为7.4年(95%CI 5.3-9.5)。

临床怎么用

  • 对SSc患者应关注恶性肿瘤风险,尤其是肺、血液系统和宫颈恶性肿瘤,并考虑在SSc诊断后约7年的间隔期内进行癌症筛查。

局限性

  • 需进一步研究明确不同恶性肿瘤亚型的危险因素,以制定癌症筛查策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: SSc is associated with increased malignancy risk, a growing cause of mortality in SSc. However, standardised incidence ratios (SIR) vary widely across studies and different malignancy subtypes. This meta-analysis aimed to determine the SIR of different malignancy subtypes and the temporal relationship with SSc diagnosis. METHODS: A systematic review and meta-analysis were conducted by searching Embase, MEDLINE and Cochrane Library databases from inception to 7 December 2024. Cohort studies reporting SIRs of malignancies in SSc patients were included. Studies where SIR was not reported were excluded. Random-effects models were used to calculate pooled estimates, while study quality was assessed using the Newcastle-Ottawa Scale. This review is registered on PROSPERO (CRD42023445876). RESULTS: Thirty-one cohort studies comprising at least 32,134 SSc patients were included. Overall malignancy risk was significantly increased (SIR 1.66; 95% CI 1.32 - 2.08). Highest risks were observed for esophageal, liver, cervical, lung, and haematological malignancies (SIR 3.35 - 13.95), while breast malignancy showed modest increased risk (SIR 1.34, 95% CI 1.00 - 1.80) that was not statistically significant. High-quality studies confirmed these associations except for esophageal malignancy, with only one high quality study for liver malignancy. There was a mean interval of 7.4 years (95% CI 5.3 - 9.5) between SSc and malignancy diagnosis. CONCLUSION: Our findings confirm an increased malignancy risk, particularly lung, haematological and cervical malignancies, and an approximate 7-year interval between SSc diagnosis and malignancy development. Further studies are needed to clarify the risk factors for different malignancy subtypes to develop cancer screening strategies. FUNDING: NIL.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Teoh WS, Raghupathy J, Kanneganti A, et al. Incidence of malignancy in systemic sclerosis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2026. PMID: 42322931. doi:10.1016/j.semarthrit.2026.153006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。